DMK Pharmaceuticals Corp. (ADMP) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1149777,
    "name": "DMK Pharmaceuticals Corp.",
    "stock_name": "DMK Pharmaceuticals Corp.",
    "full_name": "DMK Pharmaceuticals Corp.",
    "name_url": "stocks-analysis/dmk-pharmaceuticals-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "0.00",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "0.00",
    "mcapval": "",
    "mcap": "",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US00547W3079",
    "curr_date": "Nov 07",
    "curr_time": "",
    "bse_nse_vol": "2 ",
    "exc_status": "Active",
    "traded_date": "Nov 07, 2025",
    "traded_date_str": "2025 11 07",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dmk-pharmaceuticals-corp-1149777-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is DMK Pharmaceuticals Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dmk-pharmaceuticals-corp-technically-bullish-or-bearish-3546975",
        "imagepath": "",
        "date": "2025-09-20 19:44:06",
        "description": "As of 23 June 2025, the technical trend for DMK Pharmaceuticals Corp. has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish, suggesting some short-term positive momentum. However, the monthly RSI is bearish, indicating weakness over a longer time frame. Overall, the mixed signals lead to a mildly bearish outlook. The company has experienced a significant decline, with a 1-year return of -100% compared to the S&P 500's 17.14% return...."
      },
      {
        "title": "Is DMK Pharmaceuticals Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dmk-pharmaceuticals-corp-overvalued-or-undervalued-3543442",
        "imagepath": "",
        "date": "2025-09-20 18:19:34",
        "description": "As of 8 July 2024, the valuation grade for DMK Pharmaceuticals Corp. has moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company appears to be overvalued, particularly given its current P/E ratio of 0.00 and negative EV to Sales ratio of -1.82, which suggest that the market does not assign any value to its earnings or sales. Additionally, the EV to EBITDA ratio stands at 0.36, further highlighting the lack of investor confidence in the company's profitability.\n\nIn comparison to peers, DMK Pharmaceuticals Corp. shows a stark contrast with Inhibikase Therapeutics, which has an EV to EBITDA of -0.79, and Aileron Therapeutics, which has an EV to EBITDA of -1.05, both indicating challenges in their valuations as well. Notably, DMK Pharmaceuticals has experienced a 100% decline in stock value over the past year, while the S&P 500 has returned 17.14%, reinf..."
      }
    ],
    "total": 6,
    "sid": "1149777",
    "stock_news_url": "https://www.marketsmojo.com/news/dmk-pharmaceuticals-corp-1149777"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is DMK Pharmaceuticals Corp. technically bullish or bearish?

2025-09-20 19:44:06

As of 23 June 2025, the technical trend for DMK Pharmaceuticals Corp. has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish, suggesting some short-term positive momentum. However, the monthly RSI is bearish, indicating weakness over a longer time frame. Overall, the mixed signals lead to a mildly bearish outlook. The company has experienced a significant decline, with a 1-year return of -100% compared to the S&P 500's 17.14% return....

Is DMK Pharmaceuticals Corp. overvalued or undervalued?

2025-09-20 18:19:34

As of 8 July 2024, the valuation grade for DMK Pharmaceuticals Corp. has moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company appears to be overvalued, particularly given its current P/E ratio of 0.00 and negative EV to Sales ratio of -1.82, which suggest that the market does not assign any value to its earnings or sales. Additionally, the EV to EBITDA ratio stands at 0.36, further highlighting the lack of investor confidence in the company's profitability. In comparison to peers, DMK Pharmaceuticals Corp. shows a stark contrast with Inhibikase Therapeutics, which has an EV to EBITDA of -0.79, and Aileron Therapeutics, which has an EV to EBITDA of -1.05, both indicating challenges in their valuations as well. Notably, DMK Pharmaceuticals has experienced a 100% decline in stock value over the past year, while the S&P 500 has returned 17.14%, reinf...

View All News